RHHBY Stock Recent News
RHHBY LATEST HEADLINES
President Donald Trump's planned tariffs on pharmaceuticals imported into the U.S. could have wide-ranging consequences on the drug supply chain, manufacturers and American patients, some experts told CNBC. The tariffs could disrupt the complex pharmaceutical supply chain, potentially driving up the prices of drugs in the U.S. and exacerbating shortages of critical medicine.
The Danish biotech's recruitment drive began last summer when data from an early-stage trial of the drug—petrelintide—showed its potential.
Onco-Innovations' Inka Health Publishes Roche-Sponsored Study Advancing Real-World Oncology Research
VANCOUVER, BC / ACCESS Newswire / April 10, 2025 / Onco-Innovations Limited (CSE:ONCO)(OTCQB:ONNVF)(Frankfurt:W1H, WKN: A3EKSZ) ("Onco" or the "Company") is pleased to announce that its subsidiary, Inka Health Corp. ("Inka Health"), has published a significant and novel study titled Quantitative Bias Analysis for the Assessment of Bias in Comparisons between Synthetic Control Arms (the "Study") published in JAMA Network Open[1] in March 2025, addressing a critical methodological gap in real-world oncology research. The Study[2], sponsored by F.
U.S. President Donald Trump late on Tuesday reiterated he would impose tariffs on imports of pharmaceutical products that have long been spared from past trade disputes due to the potential for harm to patients.
Trump doubled down on plans to soon impose "major" pharmaceutical tariffs, while early stage startups dominated digital health funding deals in first quarter.
Just like the rest of the stock market, pharmaceutical stocks are in a funk approaching the midweek mark, and it's looking like things might be about to get even worse for this particular pocket of the stock market. On Wednesday, Reuters reported that President Donald Trump is preparing to unveil a new series of tariffs on pharmaceutical imports.
Roche Holdings AG RHHBY on Thursday presented new data at the AD/PD 2025 International Conference on Alzheimer's and Parkinson's Diseases.
David Roche, strategist at Quantum Strategy, and Victor Cha, president of the CSIS geopolitics and foreign policy department, discuss the possibility of constitutional reform in South Korea.
Cullen Roche says that markets are losing sight of the fact that things were “already dicey” economically even before tariffs. He calls the next 12-18 months “pretty worrisome.
In March, Sarepta Therapeutics, Inc. SRPT shared an update on Elevidys (delandistrogene moxeparvovec-rokl), the only approved gene therapy in patients with Duchenne muscular dystrophy.